Japan: Novartis gets Government nod for cancer treatment Kymriah at cost of $305800

Kymriah works by removing disease-fighting T-cells from individual patients, modifying them to attack cancer, and then re-infusing them back into the patients.

TOKYO: A Japanese government panel approved Novartis' cancer treatment Kymriah at a price of 33.5 million yen ($305,800) on Wednesday, marking the entry of so-called CAR-T therapy in the country.

Read Also: Novartis recalls three lots of Promacta due to potential peanut contamination

The Swiss drugmaker aims to use the one-time personalised therapy in Japan for children and young people with acute lymphoblastic leukaemia (ALL) and adult patients with diffuse large B-cell lymphoma (DLBCL).

Kymriah works by removing disease-fighting T-cells from individual patients, modifying them to attack cancer, and then re-infusing them back into the patients.

Read Also: Novartis to fight US price-fixing claims against Sandoz unit